Theravectys S.A.
TheraVectys is a French biotech startup specializing in the development of vaccines based on lentiviral vector technology. Their platform focuses on eliciting cellular immune responses, particularly T-Cell responses, to address infectious diseases and cancer. They are pioneering innovative vaccine strategies, including intranasal COVID-19 vaccines, and aim to provide safe, effective, and long-lasting immunization solutions.
Industries
Nr. of Employees
small (1-50)
Patents
Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
US-10752668-B2
View DetailsLentiviral vectors for generating immune responses against human T Lymphotrophic Virus Type 1
US-9987351-B2
View DetailsLentiviral vectors containing an MHC class I, MHC class II, or B2 microglobulin upstream promoter sequence
US-9657311-B2
View Details
Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
US-10752668-B2
View DetailsLentiviral vectors for generating immune responses against human T Lymphotrophic Virus Type 1
US-9987351-B2
View DetailsLentiviral vectors containing an MHC class I, MHC class II, or B2 microglobulin upstream promoter sequence
US-9657311-B2
View DetailsProducts
Lentiviral vector–based intranasal COVID-19 vaccine candidate
A non-integrative lentiviral vector vaccine candidate encoding the SARS-CoV-2 spike protein, formulated for intranasal administration to induce mucosal IgA and systemic cellular and humoral immunity; demonstrated preclinical protection including against variants and protection of the central nervous system in transgenic models.
Pan-coronavirus T-cell vaccine candidate (developmental)
Vaccine constructs designed to target conserved coronavirus T-cell epitopes to provide broader protection against current and future coronavirus variants.
Lentiviral vector–based intranasal COVID-19 vaccine candidate
A non-integrative lentiviral vector vaccine candidate encoding the SARS-CoV-2 spike protein, formulated for intranasal administration to induce mucosal IgA and systemic cellular and humoral immunity; demonstrated preclinical protection including against variants and protection of the central nervous system in transgenic models.
Pan-coronavirus T-cell vaccine candidate (developmental)
Vaccine constructs designed to target conserved coronavirus T-cell epitopes to provide broader protection against current and future coronavirus variants.
Services
Design, formulation, and preclinical evaluation of lentiviral vector vaccine candidates in transgenic mouse and hamster models, including assessment of systemic and mucosal immunity and CNS protection.
Upstream production process development including transient transfection workflows, process optimization for yield, and planning for stable packaging cell lines to enable scale-up.
Joint research programs with institutional partners to develop and translate lentiviral vaccine candidates from bench to preclinical proof-of-concept.
Design, formulation, and preclinical evaluation of lentiviral vector vaccine candidates in transgenic mouse and hamster models, including assessment of systemic and mucosal immunity and CNS protection.
Upstream production process development including transient transfection workflows, process optimization for yield, and planning for stable packaging cell lines to enable scale-up.
Joint research programs with institutional partners to develop and translate lentiviral vaccine candidates from bench to preclinical proof-of-concept.
Expertise Areas
- Viral vector vaccine development
- T-cell vaccine design and immunology
- Intranasal and mucosal vaccine delivery
- Preclinical model development and translational research
Key Technologies
- Lentiviral vectors (non-integrative)
- DNA-flap genetic element to enhance transduction
- Intranasal delivery platforms
- Transient plasmid transfection production (293T cells)
News & Updates
Results of the joint Pasteur-TheraVectys laboratory’s work on their Covid-19 vaccine candidate based on a lentiviral vector, demonstrating protection against variants and the central nervous system in a new pre-clinical model.
A phase of clinical trials is yet to be initiated, but animal models show promising results for intranasal delivery of the lentiviral COVID vaccine, which could induce mucosal immunity at the virus entry site.
Discussion on the diversity of viral vectors and how better screening and outfitting improve their safety and efficacy for gene transfer applications.
Exploration of lentiviral vectors in vaccine development, emphasizing their safety, long-lasting immune responses, and potential for addressing unmet medical needs.
Overview of viral vectors, their diversity, and how experts ensure their safety and effectiveness in gene transfer and vaccine development.
Discussion on the evolution of viruses and the importance of screening viral vectors for safety and efficacy.
Results of the joint Pasteur-TheraVectys laboratory’s work on their Covid-19 vaccine candidate based on a lentiviral vector, demonstrating protection against variants and the central nervous system in a new pre-clinical model.
A phase of clinical trials is yet to be initiated, but animal models show promising results for intranasal delivery of the lentiviral COVID vaccine, which could induce mucosal immunity at the virus entry site.
Discussion on the diversity of viral vectors and how better screening and outfitting improve their safety and efficacy for gene transfer applications.
Exploration of lentiviral vectors in vaccine development, emphasizing their safety, long-lasting immune responses, and potential for addressing unmet medical needs.
Overview of viral vectors, their diversity, and how experts ensure their safety and effectiveness in gene transfer and vaccine development.
Discussion on the evolution of viruses and the importance of screening viral vectors for safety and efficacy.